Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow

Rhea-AI Summary

Kytopen and Aldevron have announced a joint marketing agreement to enhance cell therapy manufacturing workflows. The collaboration combines Aldevron's Nanoplasmid vector technology with Kytopen's Flowfect Tx GMP platform for CRISPR-mediated T-cell engineering.

Key benefits of this partnership include:

• High transgene expression and improved safety from Nanoplasmid technology
• Gentle gene delivery with unlimited scale through Flowfect continuous flow technology
• Enhanced CRISPR-mediated T-cell engineering with higher yields
• Cost-effective and time-saving manufacturing process

The companies will present their joint findings at the International Society of Cell & Gene Therapy Annual Meeting in New Orleans (May 7-10, 2025). The presentation will showcase increased overall yield of final drug substance and easier manufacturing compared to viral and electroporation technologies.

Positive

• Joint marketing agreement between Kytopen and Aldevron to enhance cell therapy manufacturing workflow
• Combined technology offers higher edited-cell yields and faster production for CRISPR-based therapies
• Technology integration provides GMP-compliant process ready for clinical and commercial applications
• Partnership addresses growing patient demand in CRISPR therapy market

Negative

• No financial terms or revenue projections disclosed
• Early-stage collaboration with unproven commercial success
• Results limited to preliminary data pending presentation at ISCT

News Market Reaction

+1.54%

1 alert

+1.54% News Effect

On the day this news was published, DHR gained 1.54%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

• Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies.
• High transgene expression and improved safety profile of Aldveron's Nanoplasmid^™ vector technology and the gentle gene-delivery of Kytopen's Flowfect Tx™ platform with unlimited scale, together offer enhanced CRISPR-mediated T-cell engineering resulting in high yields.
• A poster summarizing the data will be presented at ISCT, May 7-10, 2025, in New Orleans.

CAMBRIDGE, Mass. and FARGO, N.D., April 29, 2025 /PRNewswire/ -- Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies and Aldevron, a leading global manufacturer serving organizations in the gene editing, mRNA vaccine and therapeutics, viral gene therapy, and modified gene therapy spaces; today announced, a joint marketing agreement aimed at enhancing the workflow solutions for cell therapy manufacturers. The collaboration will focus on the joint promotion of the synergies achieved by combining the Aldveron Nanoplasmid™ vector technology with Kytopen's Flowfect Tx™ GMP cellular engineering platform in CRISPR-mediated engineering of primary T Cells.

Aldveron's Nanoplasmid vector offers high transgene expression and improved safety profile while the Flowfect^® continuous flow technology ensures gentle gene delivery with unlimited scale. Together these technologies provide an enhanced CRISPR-mediated T-cell engineering workflow resulting in high yields saving cell therapy developers time in a cost-effective manner.

The two companies created a joint poster of the resulting data that Kypoten will present at the International Society of Cell & Gene Therapy ("ISCT") Annual Meeting, May 7-10, 2025, in New Orleans, LA, highlighting the increase in the overall yield of final drug substance and ease of manufacturing over viral and electroporation technologies. The data will also be featured in Kytopen's Global Showcase Oral Presentation on Thursday, May 8.

"The work with Aldevron is part of a larger, shared commitment to enable advance cell therapies by streamlining workflows to deliver greater yields of healthier cells," said Kevin Gutshall, Chief Commercial Officer at Kytopen. "The combination of our technologies provides a GMP process for delivering high-quality CAR-T cells that is now available for use in clinical and commercial applications."

"This collaboration continues to demonstrate the superior performance of our Nanoplasmid vectors across novel transfection technologies," said Anu Codaty, VP of Global Marketing and Strategy for Aldevron. "The combination of the Nanoplasmid technology with Kytopen's Flowfect^® cell engineering technology has delivered higher edited-cell yields faster, which will help meet the growing patient demand as the adoption of CRISPR-based therapies accelerates." 

In addition to the presentations, Kytopen will be available to answer any questions at booth 347 at ISCT.

ISCT Poster Presentation. Wednesday, May 7, 2025, at 6:00pm; POSTER BOARD: 1100     

CONTINUOUS FLOW TRANSFECTION WITH FLOWFECT^® TECHNOLOGY AS AN EFFICIENT, NON-VIRAL TECHNOLOGY FOR SCALABLE CRISPR-MEDIATED ENGINEERING OF PRIMARY T CELLS            

Global Showcase. 15 min Presentation, Thursday, May 8, 2025, at 6:00pm

A FULLY VALIDATED, NON-VIRAL GMP PLATFORM FOR THE MANUFACTURE OF ENGINEERED CELLS AT CLINICAL AND COMMERCIAL SCALE

For further information:

Kytopen:

Investor Contact:
Michael Chiu PhD., CEO
mchiu@kytopen.com

Business and Corporate Development Contact:
Kevin Gutshall, CCO
kgutshall@kytopen.com

Aldevron:
Ellen Shafer, Senior Director of Communications
ellen.shafer@aldevron.com
701-219-0333

About Kytopen:

The innovative leader in non-viral, continuous flow cellular engineering technologies, Kytopen, headquartered in Cambridge, Massachusetts, is transforming how cell therapies are manufactured by maximizing yields, delivering hundreds of billions of engineered cells in minutes – faster than any other technology – and thereby accelerating the discovery, development, and manufacture of advanced engineered cell therapies. Its Flowfect^® cellular engineering technology is highly tunable, gentle on cells, and has demonstrated performance across a range of cell types, payloads, and therapeutic applications. Kytopen has recently disclosed strategic partnerships with industry-leading biotechnology companies, contract development and manufacturing organizations (CDMOs), and cell therapy-focused medical centers. Kytopen continues to engage strategic partners and is committed to enabling their partners' success by providing innovative technology and developing close collaborative relationships to bring lifesaving, next generation cell therapies to patients worldwide. www.kytopen.com

About Aldevron

Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, RNA, proteins, enzymes, and other key components for the development of vaccines, gene and cell therapies, immunotherapies, and other treatments. Headquartered in Fargo, North Dakota, and as a part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. To learn more about how Aldevron is advancing biological science, visit www.aldevron.com/about-us.

View original content to download multimedia:https://www.prnewswire.com/news-releases/kytopen-and-aldevron-expedite-cell-therapy-manufacturing-through-their-collaborative-crispr-mediated-cellular-engineering-workflow-302441388.html

SOURCE Kytopen

FAQ

What are the benefits of Kytopen and Aldevron's collaboration for cell therapy manufacturing (DHR)?

The collaboration combines Aldevron's Nanoplasmid vector technology (high transgene expression, improved safety) with Kytopen's Flowfect Tx platform (gentle gene delivery, unlimited scale) to achieve higher edited-cell yields faster in CRISPR-mediated T-cell engineering, making the manufacturing process more efficient and cost-effective.

When will Kytopen present their cell therapy manufacturing data at ISCT 2025?

Kytopen will present their data at two sessions: a poster presentation on Wednesday, May 7, 2025, at 6:00 PM (Board 1100), and a Global Showcase 15-minute presentation on Thursday, May 8, 2025, at 6:00 PM in New Orleans.

How does the Flowfect Tx GMP platform improve CAR-T cell production?

The Flowfect Tx GMP platform provides a non-viral, continuous flow cellular engineering process that delivers higher yields of healthier CAR-T cells compared to viral and electroporation technologies, making it suitable for clinical and commercial applications.

What are the key advantages of Aldevron's Nanoplasmid technology for CRISPR therapy?

Aldevron's Nanoplasmid technology offers two main advantages: high transgene expression and an improved safety profile, which helps meet growing patient demand as CRISPR-based therapies become more widely adopted.

Where can investors learn more about the Kytopen-Aldevron cell therapy collaboration at ISCT 2025?

Investors can visit Kytopen at booth 347 at ISCT in New Orleans (May 7-10, 2025) to learn more about the collaboration and view their poster presentation demonstrating the enhanced CRISPR-mediated T-cell engineering workflow.